Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Scientists use it as a model compound to investigate strategies for improving the bioavailability, half-life, and tissue targeting of peptide therapeutics
39,76 Impaired synthesis of cysteine from methionine may necessitate the provision of a source of cysteine to some patients with cirrhosis
First identified in 1973 by researcher Loren Pickart, GHK-Cu emerged from observations that blood plasma from younger individuals could cause older liver tissue to synthesize proteins in patterns characteristic of younger tissue
persistent, severe abdominal pain) Hypersensitivity to DPP-4 inhibitors in the past Pregnancy/breastfeeding Some DPP-4 inhibitors are contraindicated at certain thresholds of renal impairment (see Table 2 ) Some DPP-4 inhibitors are contraindicated in hepatic impairment (see Table 3 ) Type 1 diabetes Diabetic ketoacidosis Cautions History of pancreatitis Moderate heart failure (saxagliptin only, due to limited experience) Severe heart failure (saxagliptin and vildagliptin, due to limited experience) Some DPP-4 inhibitors are cautioned at certain thresholds of renal impairment, and dose reductions may be required (see Table 2 ) Drug interactions No significant interactions have been reported between DPP-4 inhibitors and any other drugs
L- ,
